Abstract:Background and purpose: Ageing is an important risk factor of non-alcoholic fatty liver disease (NAFLD). Here, we investigated whether the deficiency of nicotinamide adenine dinucleotide (NAD(+) ), a ubiquitous coenzyme, links ageing with NAFLD. Experimental approach: Hepatic concentrations of NAD(+) , protein levels of nicotinamide phosphoribosyltransferase (NAMPT) and several other critical enzymes regulating NAD(+) biosynthesis, were compared in middle-aged and aged mice or patients. The influences of NAD(+) decline on the steatosis and steatohepatitis were evaluated in wild-type and H247A dominant-negative, enzymically-inactive NAMPT transgenic mice (DN-NAMPT) given normal or high-fat diet (HFD). Key results: Hepatic NAD(+) level decreased in aged mice and humans. NAMPT-controlled NAD(+) salvage, but not de novo biosynthesis pathway, was compromised in liver of elderly mice and humans. Given normal chow, middle-age DN-NAMPT mice displayed systemic NAD(+) reduction and had moderate NAFLD phenotypes, including lipid accumulation, enhanced oxidative stress, triggered inflammation and impaired insulin sensitivity in liver. All these NAFLD phenotypes, especially release of pro-inflammatory factors, Kupffer cell accumulation, monocytes infiltration, NLRP3 inflammasome pathway and hepatic fibrosis (Masson's staining and α-SMA staining), deteriorated further under HFD challenge. Oral administration of nicotinamide riboside, a natural NAD(+) precursor, completely corrected these NAFLD phenotypes induced by NAD(+) deficiency alone or HFD, whereas adenovirus-mediated SIRT1 overexpression only partially rescued these phenotypes. Conclusions and implications: These results provide the first evidence that ageing-associated NAD(+) deficiency is a critical risk factor for NAFLD, and suggest that supplementation with NAD(+) substrates may be a promising therapeutic strategy to prevent and treat NAFLD.

Quantitative Acetylomics Reveals Dynamics of Protein Lysine Acetylation in Mouse Livers During Aging and Upon the Treatment of Nicotinamide Mononucleotide

Nicotinamide Mononucleotide Administration Amends Protein Acetylome of Aged Mouse Liver

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Β-Nicotinamide Mononucleotide Supplementation Prolongs the Lifespan of Prematurely Aged Mice and Protects Colon Function in Ageing Mice.

Nicotinamide Effects on the Metabolism of Human Fibroblasts and Keratinocytes Assessed by Quantitative, Label-Free Fluorescence Imaging

L-arginine Metabolism Ameliorates Age-Related Cognitive Impairment by Amuc_1100-mediated Gut Homeostasis Maintaining

Nicotinamide Mononucleotide Administration Restores Redox Homeostasis via the Sirt3-Nrf2 Axis and Protects Aged Mice from Oxidative Stress-Induced Liver Injury

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner

Research advances in the function and anti-aging effects of nicotinamide mononucleotide

The Impacts of Short-Term NMN Supplementation on Serum Metabolism, Fecal Microbiota, and Telomere Length in Pre-Aging Phase

Integrated Transcriptome, Proteome, Acetylome, and Metabolome Profiling of Mouse Liver During Normal Aging

β-Nicotinamide Mononucleotide Supplementation Prolongs The Lifespan Of Premature Ageing Mice And Protects Colon Function In Ageing Mice

Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatment

Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions

Identification of adrenergic presynaptic and postsynaptic protein locations at neuromuscular junctions, their decrease during aging, and recovery by nicotinamide mononucleotide administration

Metabolite accumulation from oral NMN supplementation drives aging-specific kidney inflammation

Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects

Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice